


# BIOSIMILARS: A Safe & Effective Option for Patients

In the U.S., biosimilar usage and approvals are on the rise; access to these safe, effective treatments offer patients improved health outcomes. For more information, visit [www.biosimilarscouncil.org](http://www.biosimilarscouncil.org).



A biosimilar is a biologic medicine that is

**highly similar**  
to a brand biologic medicine.

## 4 Approved



FDA has approved 4 biosimilars<sup>1</sup> to treat patients suffering from RA, Crohn's Disease, cancer, psoriasis and other conditions;

**60+**  
more in development<sup>2,3</sup>


## 20 Available



In Europe, 20 biosimilars available in at least 8 therapeutic classes<sup>4</sup>



Same safety and efficacy as their biologic counterpart



Same mechanism of action



Rigorous FDA testing and review; Less cost to patients and the health system



Companies that manufacture biosimilars are committed to providing safe, effective products

Biosimilars are  
**safe, effective, more affordable and offer improved patient access.**




safe



effective



affordable



access

Visit us:

<http://biosimilarscouncil.org/>



/Biosimscouncil



@biosimscouncil

#### References

1. Big Developments in Biosimilars. Available at: <http://bit.ly/2nVOzdc>. Accessed March 20, 2017.
2. Biosimilars Implementation: Testimony of Janet Woodcock, M.D. to the U.S. House of Representatives February 4, 2016. Available at: <http://bit.ly/2nmE2bc>. Accessed March 13, 2017.
3. Biosimilars to Drive Modern Manufacturing Approaches. Available at: <http://bit.ly/2nmE2bc>. Accessed March 13, 2017.
4. Biosimilars in the EU: Lower Costs, Increased Patient Access. Available at: <http://bit.ly/2nmy0HX>. Accessed March 13, 2017.